Navigation Links
Pharmos Corporation Reports 2008 Second Quarter Results
Date:8/7/2008

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the second quarter ended June 30, 2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the second quarter 2008 compared to a net loss of $4.6 million, or $0.18 per share, in the second quarter 2007. Cash and cash equivalents totaled $9.0 million at June 30, 2008.

The decrease in net loss for the second quarter 2008 is due primarily to a 46% decrease in operating expenses to $2.6 million from $4.9 million in the second quarter 2007. The decline in operating expenses resulted from a 41% decrease in gross research and development expenses to $2.1 million compared to $3.7 million in the second quarter 2007. Also general and administrative expenses decreased 66% to $0.5 million from $1.3 million in the second quarter 2007.

During the second quarter, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients. The Phase IIb trial is expected to enroll approximately 480 patients in about 70 sites in the United States. Costs of $1,470,000 were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. During the second quarter, the Company engaged a second CRO to identify and manage additional sites. As the Company is currently behind its planned enrollment schedule, additional expenses were incurred in conducting a centralized advertising campaign to enhance patient enrollment. Dextofisopam was one of the compounds the Company obtained through the acquisition of Vela Pharmaceuticals Inc which closed in October 2006. The continued development of this compound through late-stage clinical testing will
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Pharmos Corporation Reports 2008 First Quarter Results
3. Pharmos Corporation Completes Initial Closing of Private Placement
4. Pharmos Corporation Announces Board and Management Changes
5. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
6. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
7. Pharmos Corporation Reports 2007 Third Quarter Results
8. Pharmos Issues Letter to Shareholders
9. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
10. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
11. PolyOne Corporation Announces an Exclusive License Agreement with Battelle for Bio-Plasticizer Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
(Date:2/26/2015)... 26, 2015 Innovation is more ... from unexpected parts of the world and transforming ... agriculture to manufacturing to health care, disruption is ... realities and socio-political trends shake the foundations of ... ingredient for CEOs to survive the next wave ...
(Date:2/26/2015)... February 26, 2015 Regis Technologies ... development of oncology drug substances. , Regis Technologies is ... their new Potent Compound Suite (PCS) for 2015. , ... square foot, cGMP facility in Morton Grove, Illinois. The ... of potent compounds up to about one kilogram per ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Regis Extends cGMP Services to Oncology Market 2
... Five song Bits and Pieces is a good metaphor for the ... and early stage financing efforts to get life science companies off ... together some of these pieces so the tapestry doesnt fall apart. ... remarked on my negligence in mentioning other seed and early stage ...
... Without technology innovators, would regulators have anything to do? ... are a reminder that for every breakthrough in fields ... up to slow the sprint toward progress. , ,That ... was always based on scientific inquiry, but sometimes the ...
... With the University of Wisconsin System and the state's ... separate statewide networks, Gov. Jim Doyle has stepped in ... more sensible for taxpayers to have a unified nework ... , ,Initial discussions last year about a unified network ...
Cached Biology Technology:More Midwest Seed-Stage Life Science VCs 2More Midwest Seed-Stage Life Science VCs 3More Midwest Seed-Stage Life Science VCs 4More Midwest Seed-Stage Life Science VCs 5More Midwest Seed-Stage Life Science VCs 6Technology regulation spurred by a mix of science and politics 2Technology regulation spurred by a mix of science and politics 3Governor tells UW to scrap network plans 2
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , a ... will showcase its EyeLock ID technology integrated in a 3D ... Oak Ridge National Laboratory (ORNL) at the 2015 ... authentication technology is being used to validate the driver and ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... ecosystem below an Antarctic glacier and learned that it survived ... growth. Described in the April 17 issue of ... a pool of brine trapped below Taylor Glacier and next ... Priscu , co-author of the Science article. Priscu ...
... over, Y chromosome it,s time X got some ... chromosome associated with being female, University of California, Berkeley, ... history of the X chromosome is every bit as ... important clues to the origins and benefits of sexual ...
... Sven Enerbck, Professor at the Institute of Biomedicine at the ... scientists who published their results in The New England ... Enerbck and others show that adults use brown fat to ... new possibilities in treating overweight and obesity. It has ...
Cached Biology News:Ancient ecosystem thrives millions of years below Antarctic glacier 2The story of X -- evolution of a sex chromosome 2The story of X -- evolution of a sex chromosome 3The story of X -- evolution of a sex chromosome 4
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5...
... fastest automated perfusion system. For real-time ... physiology, biophysics, electrochemistry, or general liquid-handling ... 1.5-4 millisecond accuracy Run experiments ... for accuracy and flexibility Turnkey ...
Mycoplasma tested...
Biology Products: